Thomas H Silberg, currently CEO of GenWay Biotech, is a seasoned professional in the Healthcare Industry with substantial executive level experience, in major branded pharmaceuticals, medium sized biotech, start up biotech and generic IV drug manufacturing and commercialization. He has led multiple strategic transactions including a company divestiture, a public company spin out, asset acquisitions and partnerships. He has consistently grown both revenue and earnings characterized most recently by APP Pharmaceuticals revenue growth of 23.1% cagr (2005-2009). His leadership skills have guided companies through many organizational challenges ranging from building a start up biotech company to integrating a North America based company with a European based global healthcare organization. He has successfully managed numerous company reorganizations targeted at process improvement, creating new capabilities, building needed infrastructure and downsizing.